Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide Imaging Study in Hormono-Sensitive Metastatic Prostate Cancer
NCT02815033Phase 2Completed
- Sponsor
- European Uro-Oncology Group
- Start
- Jul 2015
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide in prostate cancer (PCa), sponsored by European Uro-Oncology Group. Started Jul 2015; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02815033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02815033.